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During prolonged fasting, the liver receives an influx of 
carbon substrates from adipose tissue lipolysis and skeletal 
muscle lactate production and proteolysis. The liver must 
convert these substrates into glucose and ketones for energy 
use in extrahepatic tissues, most notably the brain, via pro-
cesses that are fueled by high level fatty acid oxidation. In 
mice, the marked influx of fatty acids leads to intrahepatic 
triglyceride accumulation (steatosis) despite high rates of 
fatty acid oxidation. Although a number of studies have ex-
amined the effects of fasting on hepatic intermediary me-
tabolism, some metabolic pathways remain understudied.
Hepatic triglyceride synthesis is generally believed to use 
primarily glycerol-3-phosphate as an initial substrate. Fatty 
acyl chains are esterified to glycerol-3-phosphate by acyl-
transferases to form lysophosphatidic acid and then phos-
phatidic acid (PA), which is converted into diacylglycerol 
(DAG) by the PA phosphohydrolases (1). Alternatively, 
monoacylglycerol (MAG), which is composed of one fatty 
acid and a glycerol backbone (unphosphorylated), can be 
directly converted into DAG through acylation by MAG 
acyltransferases (MGATs, gene symbol Mogats) (1, 2). The 
MGAT pathway is highly active in the intestine, where it is 
involved in dietary fat absorption (3–5). However, much 
less is known about the MGAT enzymes in other tissues 
with high rates of triglyceride synthesis, such as adipose tis-
sue and liver. Mice have two functional MGAT isoforms, 
while humans have three (4–7). In mice, Mogat1 is highly 
expressed in liver, stomach, and adipose tissue, while 
Mogat2 is the intestinal isoform (4, 6, 8).
MGAT activity increases in liver during times of high fat 
oxidation in multiple animal models and has been sug-
gested to retain essential fatty acids by preventing their 
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catabolism during energy deprivation (9, 10). Recently, 
several groups have shown an important function of 
Mogat1 in obesity-related nonalcoholic fatty liver disease 
(9, 11–14). Mogat1 expression was induced in liver of obese 
mice with hepatic steatosis and the expression of Mogat1 in 
this context was driven by PPAR. Strategies to suppress 
Mogat1 with RNAi methodology markedly improved he-
patic insulin resistance (12, 13) and reduced hepatic ste-
atosis in some models (13). While recent work with 
whole-body Mogat1 knockout mice has questioned the con-
tribution of this gene to tissue MGAT activity (15), acute 
suppression of Mogat1 expression markedly reduced MGAT 
activity in steatotic liver (12), suggesting chronic compen-
sation in knockout mice.
Herein, we demonstrate that the hepatic expression of 
Mogat1 and MGAT activity is increased in the liver of mice 
undergoing prolonged fasting. Furthermore, hepatic 
Mogat1 expression is dependent on PPAR, which is a 
master regulator of the hepatic fasting response (16, 17). 
We demonstrate that mice with antisense oligonucleotide 
(ASO)-mediated acute knockdown of Mogat1 have de-
creased MGAT activity and lower liver triglyceride content. 
Interestingly, Mogat1 suppression during fasting also led to 
reduced expression of PPAR target genes; an effect that 
was reversed by the synthetic PPAR ligand, WY-14643. 
These data suggest that Mogat1 is a fasting-induced PPAR 
target gene that may feed-forward to enhance PPAR activ-
ity and the systemic response to food deprivation.
MATERIALS AND METHODS
Animal studies
All mouse studies were approved by the Institutional Animal 
Care and Use Committee of Washington University. All mice were 
in the pure C57BL/6J background. Male whole-body PPAR-null 
mice were obtained from Taconic. Mice were group housed and 
maintained on standard laboratory chow on a 12 h light/dark cy-
cle. On the day of the experiment, 10- to 12-week-old male and 
female mice were randomly assigned to receive either ad libitum 
(fed) access to standard laboratory chow or food deprived (fasted) 
for the times indicated. Fasts were timed such that all mice were 
euthanized at 0900. Liver tissue was harvested and immediately 
frozen in liquid nitrogen until further use. Blood was collected by 
venipuncture of the inferior vena cava in EDTA-coated tubes and 
plasma was frozen after collection by centrifugation.
ASO treatments were performed as previously described (12). 
Briefly, 8-week-old male C57BL/6J mice (Jackson Laboratory, Bar 
Harbor, ME) were given twice weekly intraperitoneal injections of 
ASO directed against Mogat1 [5′-GATCTTGGCCACGTGGA-
GAT-3′ (20-mer)] or scramble control (Ionis, Pharmaceuticals, 
Inc., Carlsbad, CA; 25 mg/kg body weight) for 3 weeks. Mice were 
then fasted for 24 h or continued to receive ad libitum access to 
food. Knockdown was confirmed by the quantitative (q)PCR 
methods described below using the following sequences against 
Mogat1: forward 5′- TGGTGCCAGTTTGGTTCCAG-3′ and reverse 
5′-TGCTCTGAGGTCGGGTTCA-3′.
For studies involving PPAR ligand administration, mice were 
treated with ASO as before and given a one-time oral gavage of 
vehicle alone (0.5% carboxymethyl cellulose) or WY-14643 (100 
mg/kg body weight; Cayman Chemical, Ann Arbor, MI) (18). 
Mice were then immediately fasted for 18 h and harvested as 
before.
mRNA isolation and gene expression analysis
Total liver RNA was isolated using RNA-BEE (Iso-Tex Diagnos-
tics, Friendswood, TX) according to manufacturer’s instructions. 
RNA was reverse transcribed into cDNA using TaqMan high-
capacity reverse transcriptase (Life Technologies, Woolston, WA). 
Quantitative RT-PCR was performed using Power SYBR green 
and measured on an ABI PRISM 7500 sequence detection system 
(Applied Biosystems, Foster City, CA). Results were normalized 
to 36B4 expression and calculated using the 2ct method and 
shown as arbitrary units relative to control groups. Primer se-
quences are listed in Table 1.
Liver and plasma metabolites
Frozen liver tissue (100 mg/ml) was homogenized in ice-cold 
PBS and lipids were solubilized in 1% sodium deoxycholate via 
vortexing and heating at 37°C for 5 min. Hepatic triglyceride con-
tent was measured using a commercially available triglyceride 
colorimetric assay kit as previously described (19). Plasma samples 
were analyzed as previously described (12). Briefly, plasma NEFAs 
were measured using a colorimetric assay from WAKO (Wako 
Diagnostics, Richmond, VA). Plasma triglyceride was measured 
using the Thermo Fisher kit and plasma ketone bodies were 
measured using a 3-hydroxybutyrate enzymatic assay (WAKO). 
For blood glucose measurements, blood was procured from the 
tail just prior to euthanization, and glucose was measured using a 
OneTouch Ultra glucometer (LifeScan Inc.). Plasma insulin and 
glucagon were measured by Singulex immunoassay and mouse 
Mercodia glucagon ELISA – 10 L, respectively, by the Washington 
University Core Laboratory for Clinical Studies.
MGAT enzymatic activity assay
MGAT activity was determined as described (12) with slight 
modification. Membrane fractions were isolated from 50 mg of 
liver tissue by homogenization in membrane buffer [50 mM Tris-
HCl (pH 7.4), 1 mM EDTA, 250 mM sucrose, and complete pro-
tease inhibitors tablets (Roche Diagnostics, Indianapolis, IN)]. 
Homogenates were precleared of whole cell debris at 500 g for 
10 min at 4°C followed by ultracentrifugation at 21,000 g for 1 h at 
4°C. The resultant pellet was suspended by vigorous pipetting in 
membrane buffer without protease inhibitors. Fifty micrograms 
of membrane were incubated in 5 mM MgCl2, 1.25 mg/ml BSA, 
200 mM sucrose, 100 mM Tris-HCl (pH 7.4), 20 M 14C-oleoyl-
CoA (American Radiolabeled Chemicals), and 200 M sn-
2-oleoylglycerol for 5 min. The reaction was terminated with 
50 l of 1% phosphoric acid. Lipids were extracted in 2:1 v/v% 
CHCl3:methanol and separated by thin-layer chromatography in 
hexane/ethyl ether/acetic acid (80:20:1, v/v/v %). Samples were 
run against standards for FFA, DAG, and triglyceride and corre-
sponding spots were scraped from the plate and 14C-radioactivity 
was measured via scintillation counter. Backgrounds were calcu-
lated from reaction mixtures without membrane fractions.
PPAR activity assay
Mice were treated with ASO for 3 weeks as described above and 
then fasted overnight. Nuclear fractions were isolated from fresh 
liver samples according to the manufacture’s protocol (Nuclear Ex-
traction Kit 10009277; Cayman Chemical). Briefly, 250 mg of liver 
tissue were homogenized in 750 l of ice-cold hypotonic buffer 
supplemented with 1 mM DTT and 0.01% NP-40 using a Dounce 
homogenizer. After a 15 min incubation on ice, the cytosol was re-
moved via a 300 g spin at 4°C for 10 min. The pellets were resus-
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ice. Cells were lysed with the addition of 1% NP-40 and cytosolic 
fractions removed after a 14,000 g spin at 4°C for 30 s. Nuclei were 
lysed in 100 l of nuclear extraction buffer for 30 min. The nuclear 
fractions were removed following a 14,000 g spin at 4°C for 10 min 
and then immediately flash-frozen in liquid nitrogen.
PPAR activity was measured according to manufacturer’s pro-
tocol (PPAR Transcription Factor Assay Kit 10006915; Cayman 
Chemical). Briefly, 25 g of nuclear lysates were added in dupli-
cate to each well of the ELISA plate and incubated overnight at 
4°C. The plate was read at 450 nm and the results were normal-
ized to control ASO-treated fasted mice following the subtraction 
of nonspecific binding wells as the blank.
Liver and serum lipid extraction for LC/MS
Liver and serum samples were treated with 3 ml of 2:1 
chloroform:methanol. Liver samples were homogenized in the 
presence of the following internal standards: U-13C-labeled palmi-
tate (100 pmol/mg), C17:0 MAG (10 pmol/mg), and C17:0 DAG 
(10 pmol/mg). For serum samples, all internal standards were 
adjusted to 10 pmol/l serum. Lipid extraction was performed by 
vortexing for 1 min and bath sonication for 30 min. After adding 
1 ml of 0.1 M Tris buffer, samples were vortexed (1 min) and bath 
sonicated (30 min). The organic and aqueous layers were then 
separated by centrifugation at 3,000 g for 20 min. The organic 
layer was collected. Chloroform (1 ml) was mixed with the aque-
ous layer followed by vortexing, bath sonication, and centrifuga-
tion as described above. The organic layers were combined, dried 
by N2 gas, and reconstituted in 200 l of 9:1 methanol:chloroform. 
The extract was transferred to an LC vial for MS analysis.
LC/MS analysis
LC/MS analysis of liver and serum extracts was performed by 
using an Agilent 6530 or 6540 quadrupole TOF mass spectrome-
ter with an ESI source. Separations were achieved by using an Agi-
lent 1290 capillary UPLC system. Samples were either analyzed in 
positive ionization mode with a Cortex T3 column (2.7 m, 150 × 
2.1 mm inner diameter; Waters) or in negative ionization mode 
with a Luna aminopropyl column (3 m, 150 × 2.0 mm internal 
diameter; Phenomenex). The T3 column was used with the follow-
ing mobile phases: A = 95% water, 5% methanol, 5 mM ammonium 
acetate, 0.1% formic acid (pH 3.14); B = 90% isopropanol and 
10% methanol. The following linear gradient was applied: 0 min, 
30% B; 10 min, 70% B; 30 min, 87.5% B; 31 min, 100% B; 40 min, 
100% B. The aminopropyl column was used with following mo-
bile phases: A = 95% water, 5% acetonitrile, 10 mM ammonium 
acetate, and 10 mM ammonium hydroxide; B = 95% acetonitrile 
and 5% water. The following linear gradient was applied: 0 min, 
95% B; 2 min, 95% B; 15 min, 50% B; 20 min, 0% B; 25 min, 0% 
B. The injection volumes were 2 l. The flow rate was 200 l/min. 
The column temperature was maintained at 37°C. Mass detection 
was set from m/z 100 to 1,700 with a scan rate of 1 spectra/s. The 
ESI source parameters were: nebulizer pressure, 30 psi; nozzle 
voltage, 1,000 V; sheath gas temperature, 300°C; flow rate, 11 li-
ters/min; drying gas, 12 liters/min; gas temperature, 300°C; capil-
lary voltage, 3,000 V; fragmentor voltage, 100 V. Data analysis was 
performed with the Agilent Profinder software. The absolute 
quantitation of lipids in picomoles per milligram of liver or pico-
moles per microliter of serum was achieved by measuring the area 
under the extracted ion chromatogram peak. Data were normal-
ized to an internal standard (U-13C palmitate for FFAs, C17:0 
MAG for MAGs) to correct for extraction efficiency.
Statistical analysis
Data were analyzed via SPSS software. Independent samples 
t-tests, one-way ANOVA, or factorial ANOVAs with Bonferonni cor-
rections were performed. Prior to analysis, normality and equal 
variance of samples was determined by Kolmogorov-Smirnov test-
ing and Levene testing, respectively. If these conditions were vio-
lated logarithmic transformation intended to produce data to 
satisfy normality and equal variance assumptions were used. Oth-
erwise, nonparametric methods (e.g., Kruskal-Wallis for one-way 
ANOVAs with Mann-Whitney U post hoc analysis and Friedman’s 
test for two-way ANOVAs) were used as an alternative to the more 
standard analyses. P < 0.05 was considered significant.
RESULTS
Mogat1 expression is induced in fasted liver  
in a PPAR­dependent manner
Fasting is a physiologic stimulus associated with high rates 
of hepatic fatty acid oxidation and increased accumulation 
TABLE 1. Primer sequences for qPCR
Mouse Forward Reverse
36B4 gca gac aac gtg ggc tcc aag cag at ggt cct cct tgg tga aca cga agc cc
Mogat1 tgg tgc cag ttt ggt tcc ag tgc tct gag gtc ggg ttc a
Mogat2 tgg gag cgc agg tta cag a Cag gtg gca tac agg aca ga
Mgll cgg act tcc aag ttt ttg tca ga gca gcc act agg atg gag atg
Atgl gga cac ctc aat aat gtt ggc ctt gag cag cta gaa caa tg
Dgat1 tgc agt ttg gag acc gcg agt t cac cca ttt gct gct gcc atg t
Napepld agc gcc aag cta tca gta tcc tca gcc atc tga gca cat tcg
Lpin1 ccc tcg att tca agg cac ct gca gcc tgt ggc aat tca
Lpin2 gaa gtg gcg gct ctc tat ttc aga ggg tta cat cag gca agt
Angptl4 cat cct ggg acg aga tga act tga caa gcg tta cca cag gc
Apoc3 ggt cca gga tgc gct aag ta tgc tcc agt agc ctt tca gg
Acox1 gga tgg tag tcc gga gaa ca agt ctg gat cgt tca gaa tca ag
Cpt1a gga cgc gcc cat cg cca ctg tag cct ggt ggg t
Acadm gga aat gat caa caa aaa aag tat tt atg gcc gcc aca tca ga
Acadl cct ccg ccc gat gtt gtc att c gct gtc cac aaa agc tct ggt gac ac
Bdh1 ttc ccc ttc tcc gaa gag c ccc aga ggg tgc atc tca tag
Hmgcs2 acc tgc ggg cct tgg at ggt gaa aag gct ggt tgt ttc c
Pck1 ggg tgc aga atc tcg agt tg cac cat cac ctc ctg gaa ga
Ppara act acg gag ttc acg cat gtg ttg tcg tac acc agc ttc agc
Pparg1 gga aga cca ctc gca ttc ctt gta atc agc aac cat tgg gtc a
Pparg2 tcg ctg atg cac tgc cta tg gag agg tcc aca gag ctg att
Crebh cct gtt tga tcg gca gga c cgg ggg acc ata atg gag a
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of hepatic triglyceride. We fasted mice for 4, 18, or 24 h 
and found that intrahepatic triglyceride content was in-
creased after 18 and 24 h of fasting (Fig. 1A). Given our 
interest in the MGAT enzymes that are involved in glycero-
lipid synthesis, we also quantified their gene expression 
and found that fasting induced the expression of Mogat1, 
but not Mogat2 (Fig. 1B). Total hepatic MGAT activity was 
also increased after 18 and 24 h fasting (Fig. 1C).
Previous work has shown that Mogat1 is target gene of 
the PPAR family of nuclear receptors, particularly PPAR 
(12, 13, 20). However, in this experiment, the expression 
of Mogat1 was highly dependent on PPAR. Indeed, the 
fed and fasted expression of Mogat1 was markedly dimin-
ished in whole-body PPAR-null mice compared with wild-
type controls, whereas Mogat2 expression tended to be 
increased in whole-body PPAR-null mice in both fed and 
fasted conditions (Fig. 1D). These data demonstrate that 
Mogat1, but not Mogat2, is induced in liver by fasting and 
that its expression is highly dependent on PPAR.
Mogat1 ASO treatment lowers Mogat1 expression and 
activity in liver and adipose tissue
We utilized an acute model of Mogat1 knockdown using 
ASOs to determine Mogat1 function during fasting (12). 
Mice were treated for 3 weeks with ASOs directed against 
Mogat1 or scramble control, and then fasted for 24 h or 
continued receiving ad libitum access to food. As expected, 
Mogat1 ASO suppressed hepatic Mogat1 gene expression 
(Fig. 2A). Mogat1 knockdown did not lead to a compensa-
tory increase in Mogat2 expression in liver (Fig. 2A). Further-
more, 24 h fasting increased total hepatic MGAT activity, 
while Mogat1 knockdown led to reduced MGAT activity 
during fasting, indicating the contribution of Mogat1 to 
total hepatic MGAT activity in fasting (Fig. 2B). Previous 
work has suggested that ASOs administered by intraperito-
neal injection may affect the expression of the targeted 
gene in adipose tissue. Indeed, epididymal white adipose 
tissue (eWAT) Mogat1 expression was significantly reduced 
following ASO treatment (Fig. 2C). However, eWAT tissue 
MGAT activity was decreased by ASO treatment only in the 
fed state (Fig. 2D). Furthermore, Mogat1 ASO treatment 
did not affect adipose tissue weight (Fig. 2E). Fasting re-
duced blood glucose levels in both fasting conditions, but 
was not significantly different among ASO treatment groups 
(Table 2). Interestingly, plasma glucagon levels were in-
creased by Mogat1 ASO treatment in both the fed and fasted 
states when compared with control ASO treatment (Table 2). 
However, plasma insulin and glucose levels were unaffected 
by Mogat1 ASO treatments, suggesting that glucagon levels 
do not effect glucose homeostasis in these mice (Table 2).
Reducing hepatic and adipose tissue Mogat1 expression 
results in lower intrahepatic triglyceride content
We assessed the effects of Mogat1 ASO on hepatic steato-
sis and found that fasting increased the intrahepatic con-
tent of triglyceride in both ASO groups (Fig. 3A), but 
compared with control ASO, Mogat1 ASO led to reduced 
intrahepatic triglyceride accumulation in fasted liver. LC/
MS analyses were used to determine that fasting increased 
the abundance of FFAs and MAGs in liver (Fig. 3B, C), 
including increases in many species of these lipids (Fig. 
3D, E). However, Mogat1 ASO did not affect the accumula-
tion of total hepatic FFAs or MAGs. Interestingly, several 
long-chain unsaturated MAGs were increased with Mogat1 
ASO treatment in the fed state, including MAG 20:4 
(2-arachidonoylglycerol).
We also assessed plasma metabolite concentrations after 
Mogat1 knockdown. Triglyceride concentrations were not 
affected by Mogat1 ASO, though concentrations tended to 
be lower compared with control ASO-treated mice after 
fasting (Fig. 4A). As expected, fasting increased the abun-
dance of FFAs in plasma (Fig. 4B), including increases in 
many fatty acid species (Fig. 4D). There was no effect of 
Mogat1 ASO on the concentrations of FFAs. It was also de-
termined that MAG was abundant in the plasma of both 
fed and fasted mice and there was no significant change in 
Fig. 1. Mogat1 gene expression and MGAT activity 
are increased during fasting-induced steatosis and are 
PPAR dependent. Male C57BL/6J mice were fasted 
for the times indicated or given free access to food 
(Fed) prior to euthanization. A: Liver triglycerides are 
increased during prolonged fasting in mice compared 
with fed controls. B: Gene expression of Mogat1, but 
not Mogat2, is significantly upregulated during fasting. 
C: MGAT activity was measured in hepatic membranes 
from fasting or fed mice and total activity was signifi-
cantly increased after 18 and 24 h of fasting. D: Mogat1 
induction during fasting (24 h) is PPAR dependent. 
Data are shown as mean ± SE; *P < 0.05 from fed state 
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total MAG with fasting (Fig. 4C). Interestingly, some MAG 
species (22:2 and 22:4) were robustly increased in plasma 
during fasting (Fig. 4E); but again, knockdown of Mogat1 
in liver and adipose tissue did not affect the abundance of 
these species.
Mogat1 ASO treatment lowers fasting­induced PPAR 
target gene expression
We assessed the expression of several enzymes involved 
in lipid metabolism in liver of mice treated with Mogat1 
ASO and found that Mogat1 ASO treatment unexpectedly 
led to decreased fasting-induced expression of Mgll, Dgat1, 
and Lpin2 (Fig. 5A). Because many of these genes are 
known PPAR targets, we also examined the expression of 
other genes regulated by PPAR in the context of Mogat1 
knockdown. Surprisingly, expression of several other 
PPAR targets involved in FFA oxidation, lipid metabo-
lism, and ketone generation was reduced with Mogat1 
knockdown (Fig. 5B). These genes included Angptl4, Apoc3, 
Cpt1a, Acadm, Acadl, Bdh1, and Hmgcs2. However, fasting-
induced expression of the non-PPAR target gene, Pck1, 
encoding a gluconeogenic enzyme, was not affected by 
Mogat1 ASO. To confirm that the effects of Mogat1 ASO 
treatment were not due to off target effects of ASO treat-
ment, we treated additional mice with an ASO targeting 
a separate Mogat1 sequence. Indeed, Mogat1 ASO treat-
ment reduced Mogat1 expression during fasting and 
reduced several genes involved in PPAR-mediated fatty 
acid oxidation, including Acadm and Acadl (supplemental 
Fig. S1). This pattern of metabolic gene expression sug-
gested that hepatic fatty acid oxidation and ketogenesis 
might be affected by Mogat1 ASO treatment. Total plasma 
ketone concentrations, which were increased by 24 h fast-
ing, were not significantly affected by Mogat1 ASO, but 
tended to be lower compared with control ASO-treated 
mice (Fig. 5C).
Fig. 2. Mogat1 ASO treatment suppresses fasting-
induced Mogat1 expression and MGAT activity. Male 
C57BL/6J mice were injected (intraperitoneally) 
twice weekly with ASOs targeted against Mogat1 or 
scramble control (25 mg/kg) for 3 weeks prior to fast-
ing (24 h) and liver harvest. A: Fasting mice receiving 
Mogat1 ASO had significantly lower Mogat1, but not 
Mogat2, gene expression during fasting compared with 
controls. B: Mogat1 ASO knockdown suppresses fast-
ing-induced MGAT activity compared with controls. 
C: Fasting lowered eWAT expression of Mogat1, and 
Mogat1 was suppressed in both states by Mogat1 ASO 
treatments. D: eWAT MGAT activity was lowered by 
Mogat1 ASO treatment in the fed state. E: eWAT weight 
decreased with fasting in control-treated mice, but was 
not significantly changed by the ASO treatment. Data 
are shown as mean ± SE. *P < 0.05 where indicated; 
†P < 0.05 versus fed state; n = 4–5.
TABLE 2. Plasma parameters of ASO-treated mice
Control ASO: Fed Mogat1 ASO: Fed Control ASO: Fasted Mogat1 ASO: Fasted
Blood glucose (mg/dl) 192.4 ± 6.0 175.0 ± 9.38 105.2 ± 12.3a 97.6 ± 10.9a
Plasma Insulin (pg/ml) 699.4 ± 41.6 709.6 ± 41.1 234.4 ± 38.5 329.2 ± 36.4
Plasma Glucagon (pg/ml) 9.6 ± 1.5 35.4 ± 6.4b 10.9 ± 4.9 33.0 ± 6.6 (P = 0.09)
Blood was procured from the tail vein at the time of euthanization after fasting (24 h) or ad libitum feeding 
(Fed) for blood glucose measurements. Plasma was collected after euthanization. Insulin and glucagon levels were 
measured using ELISAs. Data are shown as mean ± SE (n = 5).
aP < 0.05 versus fed state.
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The data above suggest that Mogat1 may modulate the 
hepatic fasting response via a mechanism involving PPAR. 
The expression of the transcription factor, Crebh, which 
is known to be a PPAR target gene, was decreased by 
Mogat1 ASO (Fig. 5D). Mogat1 knockdown did not affect 
the expression of Ppara, Pparg1, Pparg2, or the PPAR co-
activator, Ppargc1a, in fasted liver (Fig. 5D). To further 
confirm that Mogat1 ASO treatment lowers PPAR activ-
ity, nuclei from ASO-treated mice fasted for 18 h were 
isolated and assayed for PPAR activity. These results in-
dicated a 40% reduction in PPAR activity in mice treated 
with Mogat1 ASO (Fig. 5E), similar to the magnitude of 
reduction seen in the expression of PPAR targets in 
these mice.
PPAR ligand rescues triglyceride metabolism  
in Mogat1­deficient mice during fasting
To determine whether stimulating PPAR activity would 
reverse the effects of Mogat1 knockdown on gene expres-
sion and rescue the metabolic phenotype of fasting, we ad-
ministered a single oral gavage of vehicle or the potent 
PPAR agonist, WY-14643, to mice treated with control 
or Mogat1 ASO at the onset of an 18 h fast (Fig. 6A). The 
duration of fasting in this study was shorter (18 vs. 24 h) com-
pared with most of the studies described above. Gene ex-
pression analyses revealed that PPAR ligand treatment of 
fasted mice strikingly induced the expression of Mogat1 
(Fig. 6A), consistent with this gene being a target of PPAR. 
Conversely, Mogat2 expression was actually suppressed by 
Fig. 3. Mogat1 ASO treatment lowers hepatic triglyceride 
during fasting. A: Mogat1 ASO treatment lowered hepatic 
triglyceride content during the fasted state compared with 
control ASO-treated mice. B, C: Total hepatic FFA and 
MAG were not different between ASO treatment groups as 
measured by LC/MS. D: Individual hepatic FFA species mea-
sured by LC/MS. E: Long-chain unsaturated MAG species 
were increased by fasting, but only increased by Mogat1 ASO 
in the fed state. Data are shown as box and whisker plots, 
*P < 0.05, where indicated, †P < 0.05 vs. fed state; n = 4–5.  at W
ashington U
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WY-14643 administration. Ligand administration rescued 
the expression of Mgll, but did not change Dgat1 (Fig. 6B). 
Again, liver triglyceride content was reduced in fasted mice 
receiving Mogat1 ASO compared with ASO controls (Fig. 
6C). In contrast to the longer 24 h fasting studies described 
above, Mogat1 ASO led to reduced plasma triglyceride and 
ketone concentrations after 18 h fasting (Table 3). WY-
14643 treatment corrected hepatic triglyceride levels and 
plasma triglyceride and ketone concentration to that of 
ASO scramble control-treated mice receiving WY-14643 
(Fig. 6C, Table 3). Lastly, the expression of several other 
PPAR target genes, including Acox1, Acadm, and Cpt1a, 
during fasting was rescued by WY-14643 (Fig. 6D). These 
data are suggestive that Mogat1 deficiency leads to reduced 
PPAR activity and that providing exogenous PPAR  
ligand reverses the effects of Mogat1 depletion on these 
parameters.
DISCUSSION
MGAT activity may catalyze an important step in lipid 
metabolism, but the regulation and metabolic effects of 
this enzyme in tissues other than intestine are poorly un-
derstood. Here, we provide evidence that Mogat1 and 
MGAT activity is induced in liver of fasted mice and that 
Fig. 4. Mogat1 ASO treatment does not alter fasting 
plasma lipid levels compared with control ASO-treated 
mice. A: Plasma triglycerides were measured by colori-
metric assay and not affected by fasting or ASO treat-
ment. B, C: Plasma FFAs and MAGs were measured by 
LC/MS, and FFAs were elevated by fasting in both 
groups. D, E: Individual plasma FFAs and MAGs were el-
evated during fasting, but not changed by either ASO. 
Data are shown as box and whisker plots; *P < 0.05 where 
indicated; †P < 0.05 versus fed state; n = 5.  at W
ashington U
niv M
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this response occurs in a PPAR-dependent manner. 
MGAT activity contributes to hepatic triglyceride storage 
during fasting, possibly directly via its enzymatic activity 
and indirectly by regulating expression of other glycero-
lipid biosynthetic enzymes. Our data suggest that MGAT 
activity may indirectly regulate the expression of key en-
zymes in fatty acid metabolism by impacting PPAR activ-
ity. Indeed, Mogat1 ASO treatment reduced the expression 
of many PPAR target genes as well as PPAR activity in a 
DNA binding assay, and administering a synthetic PPAR 
ligand to mice with Mogat1 knockdown overcame the im-
paired activation of the expression of lipid metabolic en-
zymes. These findings suggest a novel role for Mogat1 in 
the hepatic fasting response.
Several observations suggest that Mogat1 plays a role in 
coordinating the hepatic fasting response, potentially via 
PPAR-dependent and -independent mechanisms. As dis-
cussed below, deactivation of Mogat1 suppressed expression 
of several PPAR target genes encoding enzymes involved 
in fatty acid oxidation and ketogenesis. Consistent with 
Fig. 5. Changes in gene expression of triglyceride synthesis pathway enzymes and PPAR target genes and 
PPAR activity during prolonged fasting in mice following Mogat1 ASO treatment. Male C57BL/6J mice were 
injected (intraperitoneally) twice weekly with ASOs targeted against Mogat1 or scramble control (25 mg/kg) 
for 3 weeks prior to fasting (24 h) and liver harvest. A: Fasting mice receiving Mogat1 ASO had significantly 
lower hepatic gene expression of glycerolipid enzymes compared with control ASO-treated mice. B: Hepatic 
PPAR target gene expression. C: Gene expression of transcriptional regulators. D: Nuclear PPAR activity in 
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this, plasma ketone concentration, which is an indirect 
readout for hepatic fatty acid oxidation and ketogenesis, 
was reduced by Mogat1 knockdown after 18 h fasting. 
Plasma triglyceride content was also significantly reduced 
in mice receiving Mogat1 ASO and fasted for 18 h. We pos-
tulate that this effect may be secondary to diminished ex-
pression of the secreted LPL inhibitors, Angptl4 and Apoc3 
(21–23), which have been suggested to reduce adipocyte 
reuptake of triglycerides in fasting conditions to direct 
them to other tissues (23). Further studies using tracers are 
required to fully measure metabolic flux with Mogat1 deac-
tivation. However, the data presented in this study suggest 
that hepatic Mogat1 is sufficient to affect systemic energy 
metabolism via its direct enzymatic and indirect transcrip-
tional regulatory effects.
PPAR not only controls the capacity for fatty acid oxida-
tion but also triglyceride synthesis in liver (16, 17). Whereas 
previous work has shown that PPAR is an important regu-
lator of Mogat1 expression in steatotic liver, in this study we 
show using whole-body PPAR-null mice that this member of 
the PPAR family controls Mogat1 expression in nonsteatotic 
fed liver and the induction of Mogat1 that occurs with fast-
ing. In fact, many genes regulating triglyceride metabolism, 
including Gpat1 and Dgat1, are directly regulated by PPAR 
activation (24–27). Previous work has shown that chromatin 
in the Mogat1 promoter is occupied by PPAR and directly 
responds to this nuclear receptor (27). In addition, the in-
duction in Mogat1 expression by either fenofibrates or fast-
ing is abolished in hepatocyte-specific PPAR-knockout mice 
(28). Interestingly, Mogat2 is unchanged by fasting, and its 
Fig. 6. Changes in gene expression of PPAR target 
genes during prolonged fasting in mice following 
Mogat1 ASO treatment and WY-1463 gavage. Male 
C57BL/6J mice were injected (intraperitoneally) twice 
weekly with ASO targeted against Mogat1 or scramble 
control (25 mg/kg) for 3 weeks. Prior to fasting (18 h) 
and liver harvest, mice received an oral gavage of ei-
ther vehicle (0.5% carboxymethyl cellulose) or PPAR 
ligand WY-14643 (100 mg/kg). A: Diagram of treat-
ment groups and Mogat1 gene expression. B: Gene 
expression of triglyceride pathway enzymes normal-
ized to fed control ASO vehicle gavaged mice. C: 
WY-14643 rescues hepatic triglyceride content in 
Mogat1 ASO-treated mice during fasting. D: Hepatic 
PPAR target gene expression. Data are shown as 
mean ± SE; *P < 0.05 versus control ASO group as in-
dicated; †P < 0.05 versus vehicle gavaged mice within 
the same ASO treatment; n = 5.
TABLE 3. - Plasma parameters in the WY-14643 study






Control ASO  
(Fasted) WY-14643
Mogat1 ASO  
(Fasted) WY-14643
Triglycerides (mg/dl) 82.57 ± 6.7 167.4 ± 31.8 84.02 ± 7.1a 119.1 ± 15.8 111.9 ± 9.8
NEFA (mmol/l) 0.38 ± 0.08 1.04 ± 0.1 0.73 ± 0.04 0.97 ± 0.11 1.08 ± 0.31
Ketones (mol/l) 132.4 ± 9.3 1,276.4 ± 69.1 891.7 ± 144.4* 1023.5 ± 132.6 988.6 ± 76.1
Blood glucose (mg/dl) 157 ± 4.5 79.4 ± 3.3 84.4 ± 3.0 89.2 ± 3.6 82.6 ± 1.8
Plasma was collected after oral gavage of vehicle or WY-14643 (100 mg/kg) and fasting (18 h) or fed. Data are 
shown as mean ± SE; fed controls shown for reference (n = 5).
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expression is actually downregulated by WY-14643 treatment 
and increased in PPAR-null mice, suggesting that dis-
tinct regulatory circuits control the expression of these two 
isoforms.
The present data suggest that Mogat1 expression is regu-
lated by PPAR and also that the induction of this enzyme 
serves as a feed-forward mechanism to further enhance 
PPAR activity. Although many aspects of the mechanisms 
still need to be worked out, one possible explanation is that 
MGAT activity is important for generating or retaining an 
endogenous ligand for PPAR in liver. Increased MGAT 
activity during energy deprivation was first noted by Xia 
et al. in 1993, (10) long before the cloning of the enzymes 
that catalyze this enzymatic activity. Subsequent publications 
suggest that MGAT activity spares essential fatty acids from 
oxidation by reesterifying these lipids in the context of 
lipolytic stimuli (9, 29). In the original studies, MGAT1 was 
shown to prefer unsaturated long-chain acyl-CoAs as a 
substrate (5). Whether one of these essential fatty acids or 
complex lipids is serving as an endogenous ligand for PPAR 
or another complex lipid downstream of MGAT activity re-
mains to be determined. Recently, deficiency in MAG lipase 
(Mgl1), another enzyme that catabolizes MAG, has been 
shown to improve insulin resistance and lower hepatic tri-
glyceride accumulation (30). One important substrate for 
Mgl1 is 2-arachidonoylglycerol, an endogenous cannabi-
noid (endocannabinoid). Some endocannabinoids are re-
ported to be PPAR ligands (31, 32). As MGAT activity 
converts MAG into DAG, thereby lowering the endogenous 
MAG pool, it is possible that MGAT may also be involved in 
endocannabinoid signaling. Hepatic 2-arachidonoylglyc-
erol (MAG 20:4) increased with Mogat1 ASO treatment in 
the fed state suggesting a possible link between Mogat1 and 
endocannabinoids. The effects of 2-arachidonoylglycerol 
elevation on PPAR activity and whether other endocan-
nabinoids are affected remain to be tested. MGAT activity 
may also not be unique in its effects on PPAR activity 
among lipid synthesis enzymes. Dgat1-null mice also have 
impaired PPAR activation in liver, muscle, and cardiac 
tissue (33). Furthermore, lipin 1, a glycerol-3-phosphate 
pathway PA phosphohydrolase, directly binds and coacti-
vates PPAR to amplify fatty acid oxidation (34). Therefore, 
PPAR may be controlled by flux through the triglyceride 
pathway and through direct interactions with triglyceride syn-
thetic enzymes themselves.
A limitation of the current study is that the ASO target-
ing Mogat1 leads to diminished expression of this enzyme 
systemically (mainly liver and adipose tissue) rather than a 
tissue-specific manner. This may be important because we 
have recently shown that Mogat1 is robustly induced in adi-
pocytes during differentiation and is involved in reesterify-
ing fatty acids to prevent their efflux from these cells 
(35). There are several points that suggest that the present 
observations are not due to adipose effects of the ASO. 
Although Mogat1 expression was decreased in adipose tis-
sue of Mogat1 ASO-treated mice compared with controls, 
there was no effect on MGAT activity in the fasted state. 
There was also no observed effect of the Mogat1 ASO on 
plasma FFAs, MAG concentration, or the relative abundances 
of several species of lipids. Lastly, our previous work has 
suggested that the effects of adipocyte MGAT activity on 
fatty acid retention is most important in the fed state and 
does not affect lipolytic flux in the fasted state (35). None-
theless, we cannot exclude the possibility that depletion of 
Mogat1 in adipose tissue by the ASO does not factor into 
the phenotype of our mice.
In conclusion, we have shown Mogat1 as a PPAR-
regulated acyltransferase responsible for increased hepatic 
MGAT activity during fasting. We have also provided evi-
dence for feed-forward regulation of PPAR activity by 
Mogat1. Further work using liver-specific knockout of multi-
ple Mogat isoforms may provide clearer evidence for MGAT 
function during fasting. This work provides a basis for 
conducting future in vivo tracer studies to determine the 
contributions of MGAT activity toward whole-body lipid 
metabolism during fasting.
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